Article Details
Retrieved on: 2024-12-31 20:11:25
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
The trial aims to evaluate the efficacy and safety of SCI-210, a proprietary combination of CBD and CannAmide, compared to standard CBD monotherapy.
Article found on: markets.businessinsider.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here